Therapy Candidate IMU-838 Shows Strong Activity in Preclinical Models of UC, Immunic Announces

Therapy Candidate IMU-838 Shows Strong Activity in Preclinical Models of UC, Immunic Announces
IMU-838, Immunic Therapeutics' lead therapy candidate for the treatment of ulcerative colitis (UC) and relapsing-remitting multiple sclerosis (RRMS), shows strong activity in cellular and animal models of disease, preclinical studies show. New unpublished data was shared by Hella Kohlhof, PhD, chief scientific officer of Immunic, during an oral presentation titled, "IMU-838 in Clinical Phase 2 – New Selective Oral Treatment for IBD," at the GI Inflammatory Diseases Summit (GIIDS), held June 24-25 in Boston. An oral, next-generation elective immune modulator, IMU-838 works by blocking the activity of dihydroorotate dehydrogenase (DHODH), an enzyme involved in the metabolism of activated immune cells. It reduces immune system overactivation and inflammation. The compound has been designed to work specifically on overactive T- and B-cells, and spare other "resting" immune cells. This ensures the immune system remains functional during treatment. Both immune cells, T-cells are responsible for destroying microbes or other harmful pathogens, while B-cells produce antibodies against threats perceived by the immune system. IMU-838 is currently being tested in two Phase 2 trials — CALDOSE-1 (NCT03341962) for UC patients, and EMPhASIS (
Subscribe or to access all post and page content.